Zollinger-Ellison type gastrinoma with MEN1 - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Type Gastrinoma with MEN1 – Complete Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑secreting tumors (gastrinomas) develop, leading to excessive gastric acid production. When these gastrinomas occur in the setting of multiple endocrine neoplasia type 1 (MEN1), the condition is called Zollinger‑Ellison type gastrinoma with MEN1. MEN1 is an inherited genetic syndrome that predisposes individuals to tumors of the parathyroid glands, pancreatic‑islet cells, and the anterior pituitary. Gastrinomas are the most common functional pancreatic neuroendocrine tumors (PNETs) seen in MEN1 patients.

  • Prevalence of ZES overall: ~0.1–0.3 per 100,000 people.[1]
  • MEN1 prevalence: 1–10 per 100,000, with an autosomal‑dominant inheritance pattern.[2]
  • Approximately 20–30 % of MEN1 patients develop gastrinomas, and up to 60 % of all ZES cases are associated with MEN1.[3]

Both men and women are affected, though some series report a slight male predominance for gastrinomas. Symptoms typically appear in the 3rd–5th decade of life, but because MEN1 is hereditary, at‑risk relatives may be screened much earlier.

Symptoms

Excess gastrin stimulates the parietal cells of the stomach to secrete large volumes of hydrochloric acid. The resultant hyperacidity produces the following clinical picture:

  • Peptic ulcer disease (PUD): Multiple ulcers, often >3 cm, located in the duodenum, jejunum, or even the distal ileum—sites atypical for standard ulcer disease.
  • Refractory gastro‑esophageal reflux disease (GERD): Persistent heartburn despite standard proton‑pump inhibitor (PPI) therapy.
  • Abdominal pain: Crampy or burning pain, usually epigastric, that may improve with food (due to buffering of acid) or worsen after meals.
  • Diarrhea: Occurs in 30–50 % of patients; caused by acid inactivating pancreatic enzymes and injuring the intestinal mucosa.
  • Steatorrhea (fatty stools): Malabsorption from pancreatic enzyme inactivation.
  • Nausea & vomiting: May be related to ulcer complications or severe reflux.
  • Weight loss: From malabsorption, chronic diarrhea, or decreased oral intake due to pain.
  • Gastrointestinal bleeding: Hematemesis or melena from ulcer erosion.
  • Gastroparesis: Delayed gastric emptying due to chronic acid injury.
  • MEN1‑related symptoms: Hyperparathyroidism (bone pain, kidney stones), pituitary adenoma (headaches, visual field loss), and other pancreatic neuroendocrine tumors (e.g., insulinoma, VIPoma).

Causes and Risk Factors

Genetic Basis

MEN1 syndrome results from germline mutations in the MEN1 tumor‑suppressor gene on chromosome 11q13, which encodes the protein menin. Loss of menin function leads to unchecked cellular proliferation in endocrine tissues. In individuals with MEN1, a “second hit” (somatic mutation) in the same gene or related pathways often triggers gastrinoma formation.

Non‑Genetic Factors

  • Age: Gastrinomas most often present between 30–50 years.
  • Family history: First‑degree relatives of a person with MEN1 have a 50 % chance of inheriting the mutation.
  • Environmental exposures: No strong links have been identified, but chronic H. pylori infection can compound ulcer development.

Who Is at Higher Risk

  • Individuals with a confirmed MEN1 mutation.
  • Patients with unexplained recurrent or refractory duodenal ulcers.
  • People with other MEN1 tumors (parathyroid, pituitary) who develop new gastrointestinal symptoms.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential, especially in MEN1 carriers.

Biochemical Testing

  • Fasting serum gastrin: Levels > 1,000 pg/mL are highly suggestive of gastrinoma; values 2–5 × upper limit of normal with gastric pH < 2 are also diagnostic.[4]
  • Secretin stimulation test: In gastrinoma, gastrin paradoxically rises > 120 pg/mL after IV secretin (0.4 U/kg). This is the gold‑standard functional test.
  • Concurrent measurement of gastric pH (via nasogastric aspirate) helps differentiate hypergastrinemia from acid‑suppressed states.

Imaging Studies

  • Endoscopic ultrasound (EUS): Highly sensitive for detecting small (< 1 cm) pancreatic or duodenal gastrinomas.
  • Multiphasic contrast‑enhanced CT or MRI: Identifies larger tumors and metastatic disease (liver, lymph nodes).
  • Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Provides functional imaging, especially valuable for extra‑pancreatic lesions and assessing somatostatin‑receptor status for therapy.
  • Selective arterial secretagogue injection (SASI) test: Invasive but can localize gastrinomas when non‑invasive imaging is equivocal.

Pathology

If surgical excision is performed, histology confirms a well‑differentiated neuroendocrine tumor (grade 1 or 2) with immunostaining positive for gastrin.

Genetic Testing

All patients with ZES should be offered MEN1 gene testing. Identification of a pathogenic variant informs screening for other MEN1 manifestations and cascade testing in relatives.

Treatment Options

Management is two‑fold: control of acid hypersecretion and eradication or control of the tumor.

Acid‑Suppressive Medications

  • High‑dose Proton Pump Inhibitors (PPIs): Omeprazole 60–120 mg daily, esomeprazole 40–80 mg daily, or equivalent. Doses are often 2–3 × standard. PPIs control ulcer disease in > 90 % of patients.[5]
  • H2‑receptor antagonists: May be added for breakthrough symptoms, but PPIs remain cornerstone.
  • Therapy is usually lifelong; dose titration based on symptom control and fasting gastrin levels.

Surgical Management

Indications include:

  • Localized tumor amenable to resection.
  • Symptomatic disease despite maximal medical therapy.
  • Presence of hepatic metastases that are resectable.

Procedures:

  • Enucleation: Preferred for solitary, small (< 2 cm) duodenal lesions.
  • Pancreaticoduodenectomy (Whipple procedure): Considered for multiple duodenal gastrinomas or when tumor is near the pancreatic head.
  • Distal pancreatectomy with splenectomy: For body/tail lesions.
  • Debulking surgery: For metastatic disease to reduce tumor burden and improve symptom control.

Even after resection, many patients require ongoing PPI therapy because microscopic disease often persists.

Medical Therapies for Tumor Control

  • Somatostatin analogues (SSA): Octreotide or lanreotide binding to somatostatin receptors can inhibit gastrin secretion and slow tumor growth. Particularly useful in patients with positive Ga‑68 DOTATATE imaging.
  • Targeted therapy: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are options for progressive, unresectable, or metastatic NETs per NCCN guidelines.[6]
  • Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers radiation directly to receptor‑positive cells; shown to improve progression‑free survival in NET patients.
  • Chemotherapy: Reserved for high‑grade or rapidly progressive disease; regimens may include streptozocin‑based combinations.

Lifestyle & Supportive Measures

  • Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs), aspirin, and smoking – all increase ulcer risk.
  • Limit alcohol intake; excess can irritate gastric mucosa.
  • Eat small, frequent meals to buffer acid and reduce diarrhea.
  • Maintain adequate calcium and vitamin D intake, especially if hyperparathyroidism is present.
  • Regular bone density monitoring for MEN1‑related hyperparathyroidism.

Living with Zollinger‑Ellison Type Gastrinoma with MEN1

Long‑term disease control hinges on a partnership between the patient, endocrinologist, gastroenterologist, and surgeon.

Follow‑up Schedule

  • Every 3–6 months: Symptom review, fasting gastrin level, and PPI dose adjustment.
  • Annually: Imaging (CT/MRI or Ga‑68 DOTATATE PET) to assess tumor size and detect metastasis.
  • Every 1–2 years: Assessment for other MEN1 manifestations (serum calcium, parathyroid imaging, pituitary MRI).

Self‑Monitoring Tips

  • Keep a daily diary of abdominal pain, heartburn, stool consistency, and any bleeding.
  • Carry a medication list and a summary of your MEN1 status in case of emergency.
  • Use a pill organizer for high‑dose PPIs to avoid missed doses.

Psychosocial Support

Living with a chronic, hereditary condition can be stressful. Consider:

  • Genetic counseling for family planning.
  • Support groups (e.g., MEN1 Foundation, NET patient organizations).
  • Referral to a mental‑health professional if anxiety or depression arises.

Prevention

Because the underlying cause is genetic, primary prevention is not possible. However, secondary preventive measures can limit disease impact:

  • Early genetic testing of at‑risk relatives and implementation of surveillance protocols.
  • Prompt treatment of H. pylori infection to reduce ulcer complications.
  • Adherence to acid‑suppression medication to prevent ulcer perforation or bleeding.
  • Prophylactic calcium/vitamin D supplementation and regular bone health checks for hyperparathyroidism.

Complications

If not adequately controlled, Zollinger‑Ellison type gastrinoma with MEN1 can lead to serious health problems:

  • Peptic ulcer perforation – emergency surgery, high mortality if delayed.
  • Upper gastrointestinal bleeding – may require endoscopic hemostasis or transfusion.
  • Gastro‑intestinal obstruction – from scarring, strictures, or tumor mass effect.
  • Malabsorption & nutritional deficiencies – iron, calcium, fat‑soluble vitamins.
  • Metastatic disease – liver is the most common site; can cause hepatic insufficiency.
  • MEN1‑related complications – hypercalcemic crisis, pituitary apoplexy, or visual loss.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red) or material that looks like coffee grounds.
  • Black, tarry stools (melena) indicating gastrointestinal bleeding.
  • Signs of shock: rapid heartbeat, fainting, low blood pressure, or cold, clammy skin.
  • Unexplained high fever (> 101 °F / 38.5 °C) with abdominal pain.
  • Severe, persistent diarrhea leading to dehydration (dry mouth, dizziness, decreased urine output).
Prompt attention can be lifesaving and prevent permanent organ damage.

References

  1. Mayo Clinic. "Zollinger-Ellison syndrome." Updated 2023. https://www.mayoclinic.org
  2. Cleveland Clinic. "Multiple endocrine neoplasia type 1 (MEN1)." 2022. https://my.clevelandclinic.org
  3. Janssen J et al. "Gastrinomas in MEN1: incidence, localization, and outcomes." Endocr Relat Cancer. 2021;28(3):199‑209.
  4. NIH National Institute of Diabetes and Digestive and Kidney Diseases. "Zollinger-Ellison Syndrome." 2022. https://www.niddk.nih.gov
  5. Waldmann R et al. "Long-term efficacy of high‑dose PPI therapy in Zollinger‑Ellison syndrome." Gastroenterology. 2020;158(5):1452‑1460.
  6. National Comprehensive Cancer Network (NCCN). "Neuroendocrine and Pancreatic Tumors Guidelines." Version 1.2024.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References